Patent ductus arteriosus (PDA) remains a prominent clinical challenge in the management of preterm infants. During fetal life, the ductus arteriosus diverts blood away from the underdeveloped lungs, ...
Credit: Getty Images. Evidence suggests that patent ductus arteriosus comprises anywhere from 5% to 10% of all congenital heart disease. Although the majority of congenital heart diseases (CHD) are ...
Active treatment of hemodynamically significant patent ductus arteriosus (PDA) in preterm infants within the first 2 weeks of life was associated with worse outcomes than expectant management.
For extremely preterm infants who have a large patent ductus arteriosus, early treatment with ibuprofen may reduce the risk of death and improve short-term outcomes. New research findings are ...
The multicentre, randomised, double-blind, placebo-controlled Baby-OSCAR trial. Participants were 653 extremely preterm infants with a large patent ductus arteriosus (diameter, ≥ 1.5 mm). In the first ...
The Society for Cardiovascular Angiography & Interventions (SCAI) has published a new position statement that provides best-practice guidance for the treatment of patent ductus arteriosus (PDA) using ...
Hosted on MSN
New guidance released to improve safety and outcomes of patent ductus arteriosus closure in premature infants
The Society for Cardiovascular Angiography & Interventions (SCAI) has published a new position statement that provides best-practice guidance for the treatment of patent ductus arteriosus (PDA) using ...
Merit Medical Systems initiates a study to evaluate the Bloom Micro Occluder System for treating patent ductus arteriosus in premature infants. Merit Medical Systems, Inc. has announced the enrollment ...
Early treatment with ibuprofen for a large patent ductus arteriosus did not result in a lower risk of death or moderate or severe bronchopulmonary dysplasia than placebo at 36 weeks of postmenstrual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback